| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5690646 | Gynecologic Oncology | 2017 | 7 Pages |
Abstract
IP administration of this novel combination was feasible and showed promising activity in this phase I trial of heavily pre-treated women with ovarian cancer. Further evaluation of this IP combination should be conducted.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Danielle A. Jandial, William E. Brady, Stephen B. Howell, Heather A. Lankes, Russell J. Schilder, Jan H. Beumer, Susan M. Christner, Sandra Strychor, Matthew A. Powell, Andrea R. Hagemann, Kathleen N. Moore, Joan L. Walker, Paul A. DiSilvestro,